Patents Examined by Richard G Hutson
  • Patent number: 10889841
    Abstract: The present invention concerns an oleaginous yeast variant of the species Rhodosporidium azoricum characterized by higher biomass yields and intra-cellular lipid accumulation useful for the production of bio-fuels higher, in determined conditions, with respect to the wild type strain of the same species. Furthermore, the invention concerns a method through which said oleaginous yeast variant of the species Rhodosporidium azoricum was obtained. The invention further concerns the lipid production by means of said variant strain of oleaginous yeast of the species Rhodosporidium azoricum.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 12, 2021
    Assignee: ENI S.p.A.
    Inventors: Giuliana Franzosi, Daniela Cucchetti, Daniele Bianchi, Silvia Galafassi, Concetta Compagno
  • Patent number: 10889808
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: March 3, 2019
    Date of Patent: January 12, 2021
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 10876101
    Abstract: A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: December 29, 2020
    Assignee: Locanabio, Inc.
    Inventors: Matthew Merrill Carter, Paul Daniel Donohoue
  • Patent number: 10858636
    Abstract: Stabilized reverse transcriptase fusion proteins including a thermostable reverse transcriptase connected to a stabilizer protein are described. Attaching the stabilizer protein to the thermostable reverse transcriptase stabilizes the fusion protein and can aid in its purification, provide increased solubility, allow for longer storage, or allow the fusion protein to be used under more rigorous conditions such as higher temperature. The stabilized reverse transcriptase fusion protein can also include a linker between the stabilizer protein and the thermostable reverse transcriptase. The stabilized reverse transcriptase fusion proteins are suitable for use in nucleic acid amplification methods such as the reverse transcription polymerase chain reaction and other applications involving cDNA synthesis.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: December 8, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Alan M. Lambowitz, Sabine Mohr, Georg Mohr, Eman Ghanem
  • Patent number: 10858640
    Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 8, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Yuri Koshimura, Miroslav Matev, Hiroyuki Sonoda
  • Patent number: 10858659
    Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: December 8, 2020
    Assignee: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Yiguang Wang, Yang Jiang, Xiaofeng Zhao, Weiqing He, Jianlu Dai
  • Patent number: 10837009
    Abstract: Mutant bacteriophage DNA ligases that have increased tolerance to salt and/or heat is provided. Methods, compositions and kits that employ the same are also provided.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 17, 2020
    Assignee: New England Biolabs, Inc.
    Inventors: Jennifer Ong, Gregory Lohman, Aine Quimby, Vladimir Potapov, John M. Pryor
  • Patent number: 10829747
    Abstract: The present disclosure provides variant Pol6 polymerase polypeptides, compositions comprising the Pol6 variant polypeptides, and methods for using the variant Pol6 polypeptides for determining the sequencing of nucleic acids, for example, by nanopore sequencing. The variant Pol6 polymerases possess decreased rates of dissociation of template from the polymerase-template complex, which result in increased processivity relative to the parental Pol6 polypeptides from which they are derived.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: November 10, 2020
    Assignees: Roche Sequencing Solutions, Inc., Roche Molecular Systems, Inc.
    Inventors: Aruna Ayer, Cleoma Arnold, Charles Schwab, Preethi Sarvabhowman, Eileen Thai, Ilya Lederman, Colin McGaw, Evan Amato, Barbara Eckert, Shawn Suko, Mara Boenitz-Dulat, Bigna Woersdoerfer, David Wunderlich
  • Patent number: 10822599
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 3, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Jeffrey C. Miller
  • Patent number: 10793900
    Abstract: The present invention discloses a novel polypeptide capable of binding Taq DNA polymerase, a polynucleotide encoding the polypeptide, a recombinant vector comprising the polynucleotide, a cell having the recombinant vector introduced therein, a method of producing the polypeptide using the recombinant cell, and a hot-start PCR composition comprising the polypeptide. The polypeptide of the present invention is capable of binding specifically to Taq DNA polymerase to inhibit the activity of the polymerase, and thus may be effectively used in hot-start PCR using Taq DNA polymerase.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: October 6, 2020
    Assignees: ENZYNOMICS CO. LTD., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Da-Eun Hwang, Yong Keol Shin, Palinda Ruvan Munashingha, So Yeon Park, Yeon-Soo Seo, Hak-Sung Kim
  • Patent number: 10793826
    Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: October 6, 2020
    Assignee: CysBio Aps
    Inventors: Hemanshu Mundhada, Alex Toftgaard Nielsen
  • Patent number: 10774318
    Abstract: An object is to identify endoglucanase and ?-glucosidase genes by isolating genomic DNA containing cellulase genes, which are classified into endoglucanases or ?-glucosidases, from Acremonium cellulolyticus, and sequencing the nucleotide sequences thereof. The inventors intensively compared the amino acid sequences of known endoglucanases and ?-glucosidases with each other to find conserved region of amino acid sequences in Acremonium cellulolyticus, and various primers were designed based on the information. PCR was carried out using the various primers thus designed and genomic DNA or cDNA as a template. As a result, gene fragments of endoglucanases and ?-glucosidases were obtained. Primers were designed based on the gene fragments, and PCR was carried out to amplify nine genes of endoglucanases and ?-glucosidases. The nucleotide sequences thereof were sequenced, and the present invention was completed.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: September 15, 2020
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventor: Fumikazu Yokoyama
  • Patent number: 10745727
    Abstract: The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3?-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: August 18, 2020
    Assignee: Nuclera Nucleics Ltd.
    Inventors: Michael C. Chen, Radu A. Lazar, Jiahao Huang, Gordon R. McInroy
  • Patent number: 10745747
    Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, modified polymerases and biologically active fragments thereof, such as modified Taq polymerases, are provided that allow for improved nucleic acid amplification. In some aspects, the disclosure provides modified polymerases having improved thermostability, accuracy, processivity and/or read length as compared to a referenceTaq polymerase. In some aspects, the disclosure relates to modified polymerases or biologically active fragments thereof, useful for amplification methods, and in practically illustrative embodiments, emulsion PCR.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 18, 2020
    Assignee: Life Technologies Corporation
    Inventors: Daniel Mazur, Eileen Tozer, Sihong Chen, Peter Vander Horn, Tommie Lincecum
  • Patent number: 10731141
    Abstract: Provided are nucleic acids encoding engineered polymerases comprising at least one modification in a motif A and/or at least one modification in a motif B of the polymerase and engineered polymerases encoded by the nucleic acids. Also provided are engineered DNA polymerases comprising a variant of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, the variant being at least 80% identical to SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 and comprising an amino acid substitution at one or more positions selected from the group consisting of L408, Y409, P410, R484, A/L485, and I486. Methods, vectors, kits, and compositions comprising the nucleic acids and compositions, methods and kits comprising the engineered polymerases are also provided.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: August 4, 2020
    Assignee: OMNIOME, INC.
    Inventor: Pinar Iyidogan
  • Patent number: 10724046
    Abstract: A method of improving lipid productivity, containing the steps of: enhancing the expression of a gene encoding the following protein (A) or (B), and improving the productivity of medium-chain fatty acids or lipids containing these fatty acids as components produced in a cell of a transformant, or the total amount of all fatty acids produced in a cell of a transformant: (A) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1; and (B) a protein consisting of an amino acid sequence having 64% or more identity with the amino acid sequence of the protein (A), and having glycerol-3-phosphate dehydrogenase activity.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: July 28, 2020
    Assignee: Kao Corporation
    Inventor: Shinji Sugihara
  • Patent number: 10724016
    Abstract: Disclosed are mutant DNA polymerases having increased 3?-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 28, 2020
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Fred Reichert, Keith Bauer, Thomas W. Myers, Nancy J. Schoenbrunner, Joseph San Filippo
  • Patent number: 10724015
    Abstract: The present invention relates to a mutant microorganism in which a gene that encodes phosphofructokinase-2 is disrupted or deleted to reduce glycolytic flux to thereby improve the ability of the microorganism to produce N-acetylglucosamine, and to a method of producing N-acetylglucosamine using the mutant microorganism. The mutant microorganism according to the present invention has advantages in that it has high resistance to various chemical substances, grows rapidly, is easily cultured, and produces N-acetylglucosamine with high efficiency, indicating that it is useful for production of a large amount of N-acetylglucosamine.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 28, 2020
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Min-Kyu Oh, Sang-Woo Lee
  • Patent number: 10717968
    Abstract: Compositions that include polymerases with features for improving entry of nucleotide analogues into active site regions and for coordinating with the nucleotide analogues in the active site region are provided. Methods of making the polymerases and of using the polymerases in sequencing and DNA replication and amplification as well as kinetic models of polymerase activity and computer-implemented methods of using the models are also provided.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: July 21, 2020
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: David R. Rank, Paul S. Peluso, David K. Hanzel, Geoff Otto, Thang Pham, Fred Christians, Arekadiusz Bibillo, Insil Park, Sonya Clark, John Lyle
  • Patent number: 10717975
    Abstract: Methods and compositions are described for selecting and identifying orthogonal aminoacyl synthetase-tRNA pairs and their use to incorporate unnatural amino acids in a site-specific manner in proteins. Specifically described is a novel E. coli tyrptophanyl synthetase-tRNA pair that functions as both an opal and amber suppressor and that incorporates tryptophan analogs into proteins.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: July 21, 2020
    Assignee: TRUSTEES OF BOSTON COLLEGE
    Inventors: Abhishek Chatterjee, James Italia